The global imfinzi market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Imfinzi is a human immunoglobulin G1 kappa monoclonal antibody that prevents programmed cell death ligand 1 from interacting with PD-1. Imfinzi is a checkpoint inhibitor medication. It is a prescription drug that is used to treat adults who have non-small cell lung cancer (NSCLC). The rising prevalence of urothelial carcinoma and lung cancer are the primary factors driving the imfinzi market globally.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Imfinzi at: https://orionmarketreports.com/request-sample/?id=103487&submit=Request+Sample%0D%0A
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, in order to stay competitive in the market. For instance-
- In January 2022, the HIMALAYA Phase-III trial found that a single priming dose of tremelimumab added to imfinzi improved overall survival (OS) statistically significantly and clinically meaningfully compared to sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment.
- In November 2020, imfinzi from AstraZeneca has been approved in the US for an additional dosing option, in the approved indications of unresectable stage-III NSCLC after chemoradiation therapy (CRT) and previously treated advanced bladder cancer. This new option is compatible with approved imfinzi dosing in ES-SCLC and will be available for patients weighing more than 30kg as an alternative to the current weight-based dose of 10mg/kg every two weeks.
- In September 2020, based on the results of the “Pacific” clinical trial, the USFDA approved imfinizi for the treatment of patients with stage-III NSCLC whose cancer is unresectable and has not progressed after chemoradiation because adding imfinizi to chemoradiation further delayed cancer progression and prolonged survival. With the inclusion of imfinzi, 50% of unresectable stage-III NSCLC patients survive 4 years from treatment, a significant improvement over the previous standard of 15% to 20%.
- In November 2019, the USFDA approved a supplemental Biologics License Application (sBLA) and awarded imfinzi priority review for the treatment of patients with previously untreated extensive-stage small-cell lung cancer, as per the AstraZeneca (SCLC).
A full report of Global Imfinzi Market is available at: https://orionmarketreports.com/imfinzi-market/103487/
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
· Competitive Landscape- AstraZeneca plc, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Imfinzi Market Report by Segment
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
